Aeterna Zentaris to Present at the H.C. Wainwright BioConnect 2021 Virtual Conference
January 05 2021 - 8:05AM
Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (the “Company”), a
specialty biopharmaceutical company commercializing and developing
therapeutics and diagnostic tests, today announced that Dr. Klaus
Paulini, Chief Executive Officer of Aeterna, will present at the
H.C. Wainwright BioConnect 2021 Virtual Conference taking place
January 11-14, 2021.
The video webcast presentation will be available
for viewing on-demand beginning Monday, January 11, 2021, at 6:00
AM ET for those registered for the event and will be accessible on
the Events page in the Investors section of the Company’s website
(www.zentaris.com).
For more information about the event, please
visit the conference website here.
About Aeterna Zentaris Inc.
Aeterna Zentaris Inc. is a specialty
biopharmaceutical company commercializing and developing
therapeutics and diagnostic tests. The Company’s lead product,
macimorelin, is the first and only U.S. FDA and European Commission
approved oral test indicated for the diagnosis of adult growth
hormone deficiency (AGHD). Macimorelin is currently marketed in the
United States under the tradename Macrilen™ through a license
agreement with Novo Nordisk where Aeterna Zentaris receives
royalties on sales. According to a commercialization and supply
agreement, MegaPharm Ltd. will seek regulatory approval and then
commercialize macimorelin in Israel and the Palestinian Authority.
Additionally, upon receipt of pricing and reimbursement approvals,
Aeterna expects that macimorelin will be marketed in Europe and the
United Kingdom through a recently established license agreement
with Consilient Health Ltd and Aeterna Zentaris will receive
royalties on sales and other potential payments.
Aeterna Zentaris is also leveraging the clinical
success and compelling safety profile of macimorelin to develop it
for the diagnosis of childhood-onset growth hormone deficiency
(CGHD), an area of significant unmet need.
The Company is actively pursuing business
development opportunities for the commercialization of macimorelin
in Asia and the rest of the world, in addition to other
non-strategic assets to monetize their value. For more information,
please visit www.zentaris.com and connect with the Company on
Twitter, LinkedIn and Facebook. Investor Contact:
Jenene Thomas JTC Team T (US): +1 (833) 475-8247 E:
aezs@jtcir.com
Aeterna Zentaris (NASDAQ:AEZS)
Historical Stock Chart
From Mar 2024 to Apr 2024
Aeterna Zentaris (NASDAQ:AEZS)
Historical Stock Chart
From Apr 2023 to Apr 2024